Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...
Main Author: | Ezio Zanon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/9/1195 |
Similar Items
-
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01) -
Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
by: Chonlatis Srichumpuang, et al.
Published: (2024-03-01) -
Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
by: Eichler H, et al.
Published: (2023-11-01) -
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
by: Davide Matino, et al.
Published: (2022-03-01) -
Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)